Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Sold by Greenhaven Road Investment Management L.P.

Greenhaven Road Investment Management L.P. lowered its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 5.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 1,975,541 shares of the company’s stock after selling 110,870 shares during the quarter. Cellebrite DI accounts for about 7.0% of Greenhaven Road Investment Management L.P.’s holdings, making the stock its 2nd biggest position. Greenhaven Road Investment Management L.P.’s holdings in Cellebrite DI were worth $43,521,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the business. True Wind Capital Management L.P. boosted its holdings in Cellebrite DI by 18.2% in the fourth quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock worth $305,358,000 after acquiring an additional 2,130,386 shares in the last quarter. FMR LLC boosted its holdings in Cellebrite DI by 89.1% during the fourth quarter. FMR LLC now owns 10,621,344 shares of the company’s stock worth $233,988,000 after purchasing an additional 5,004,587 shares during the last quarter. Pertento Partners LLP grew its position in Cellebrite DI by 26.7% in the 4th quarter. Pertento Partners LLP now owns 2,975,374 shares of the company’s stock worth $65,547,000 after purchasing an additional 626,373 shares in the last quarter. Pembroke Management LTD raised its holdings in shares of Cellebrite DI by 4.4% in the 4th quarter. Pembroke Management LTD now owns 1,992,432 shares of the company’s stock worth $43,893,000 after purchasing an additional 84,087 shares during the period. Finally, Crescent Park Management L.P. increased its position in Cellebrite DI by 8.3% in the fourth quarter. Crescent Park Management L.P. now owns 1,862,482 shares of the company’s stock worth $41,030,000 after buying an additional 142,534 shares during the last quarter. 45.88% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on CLBT. Lake Street Capital boosted their price objective on Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 14th. JPMorgan Chase & Co. lifted their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 target price on shares of Cellebrite DI in a report on Wednesday, April 2nd. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $23.43.

Cellebrite DI Stock Performance

NASDAQ CLBT opened at $18.90 on Friday. Cellebrite DI Ltd. has a fifty-two week low of $10.25 and a fifty-two week high of $26.30. The stock has a market cap of $4.53 billion, a P/E ratio of -13.60, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. The stock has a 50 day simple moving average of $19.10 and a two-hundred day simple moving average of $20.04.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Sell-side analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.